pharma · Attention Deficit Disorder With Hyperactivity · Hidradenitis suppurativa (HS) · AVTX
Avalo Therapeutics
Avalo Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US
- Founded
- 2011
- Employees
- 48
- Programs
- 17
- Drugs
- 2
- Patents
- 10
Avalo Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Avalo Therapeutics.
Avalo Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AEVI-007
Avalo Therapeutics
Multiple Myeloma
1 trial -
CERC-006
Avalo Therapeutics
Lymphatic Malformation
1 trial -
FP01
Avalo Therapeutics
Healthy
1 trial -
MDGN-002
Avalo Therapeutics
Crohn Disease
1 trial -
NFC-1
Avalo Therapeutics
22q11.2 Deletion Syndrome
1 trial -
NFC-1
Avalo Therapeutics
Attention-deficit Hyperactivity Disorder (ADHD)
1 trial -
NFC-1 100 mg
Avalo Therapeutics
Attention Deficit Disorder With Hyperactivity
1 trial
Frequently asked questions
How many clinical projects does Avalo Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.